2,129 press releases in English indexed under biotech & pharma.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young joined William Blair in May 2026 as part of a broader investment in the firm's equitie
Median Technologies is a leading provider of central imaging services and AI-powered image analysis for oncology clinical trials The Company will host an interactive session on the implementation of RANO 2.0 in central imaging review for neuro-oncology trials at booth #1098 The Company will also present an ePoster on the
The Citrus Grandis Fruit Extract Market is expected to experience significant growth through 2034, driven by increasing demand for natural ingredients across food, beverage, pharmaceutical, nutraceutical, and cosmetic applications. Derived from pomelo fruit, Citrus Grandis extract contains valuable bioactive compounds, ... Read more
Grand Prize recognizes IMM01-STEM and its potential to restore muscle function, metabolic health and quality of life as people age IRVINE, Calif., October 21, 2026--Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy agin
Alert: Claims focus on alleged misrepresentations about Doximity's revenue growth and market share as the lawsuit contends that decelerating sales, contracting net income, and a shift in how pharmaceutical customers deployed advertising budgets were not disclosed to investors. NEW YORK,...
The patient is a woman who recently travelled from Uganda and began showing symptoms on 7 October, four days after her arrival. The woman sought care at a private health facility in the capital, Abuja, on 11 October; laboratory testing confirmed the diagnosis on 20 October. She remains in isolation and is receiving medical care as investigations continue to determine the likely source of her infection and reconstruct her full travel and exposure history. Contact tracing underway WHO said the Nigerian health authorities have so far identified 44 contacts who are being monitored amid intensified efforts to find other people who may have been exposed. Infection prevention and control measures are being ramped up in the private health facility where the woman sought care. Cases in five countries Nigeria is the fifth country to detect Ebola Bundibugyo virus disease since an outbreak was declared in the Democratic Republic of the Congo (DRC) in mid-May – the deadliest in the country’s history. More than 9,500 cases and more than 4,200 deaths were recorded as of 18 October, according to latest data from the Congolese health authorities. There is currently no vaccine to treat the virus. Uganda also faced a deadly outbreak which was officially declared over in late August, while nine cases have been reported in Kenya and one in the Netherlands that are linked to the DRC. Containing virus spread The Nigeria Centre for Disease Control and Prevention has activated its incident management system to coordinate response efforts, WHO said. The UN agency stressed that rapid identification of cases, timely follow-up of contacts and effective infection prevention and control are critical to contain the spread of the virus. WHO and partners are working closely with the Nigerian health authorities to strengthen control measures, including case investigation, contact tracing, infection prevention and control. The agency is also assisting with the provision of essential supplies including personal protective equipment for health workers. Meanwhile, WHO has advised all countries in the region to sustain a high level of readiness as the DRC outbreak continues to evolve. Governments are also advised to maintain strong disease surveillance and ensure that laboratories can safely test suspected cases, among other measures. WHO has not recommended any restrictions regarding travel and trade with affected countries. Distributed by APO Group on behalf of UN News.
NeOnc (Nasdaq: NTHI) signed a MoU with the Department of Health – Abu Dhabi to support research and clinical capability in oncology and CNS
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing parenteral support needs in pediatric patients Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
ALAMEDA, Calif., Oct. 21, 2026 -- Santa Ana Bio, a clinical-stage precision immunology company, today announced that preclinical data on SAB05, its CD40-targeted glucocorticoid antibody-drug conjugate (ADC), will be presented in a poster at ACR Convergence 2026, the annual meeting of the American College of Rheumatology (ACR), taking place November 6–11, 2026, in Orlando, Florida.
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials
New white paper shows LensAI™ immunogenicity screening running at up to 43% lower cost per sequence on Amazon EC2 Hpc8a instances powered by AMD EPYC processors, making a critical drug-safety check practical at the scale AI-driven discovery now demands AUSTIN, Texas, October 21, 2026--MindWalk Holdings